Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Contemporary Amperex Technology / Equity Capital Markets

Contemporary Amperex Technology (3750 HK)

<ul>
<li>Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.</li>
<li>On the IPO front, most of the listings over the past week ended up doing well, irrespective of overall demand.</li>
<li>On the placements front, there was a lockup release for <a href="https://www.smartkarma.com/entities/contemporary-amperex-technology-catl-co-limited" target="_blank" data-smartkarma-citation="entities:45179:1" rel="noopener">Contemporary Amperex Technology (CATL) (3750 HK)</a>, along with a number of other placements.</li>
</ul>


Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.
On the IPO front, most of the listings over the past week ended up doing well, irrespective of overall demand.
On the placements front, there was a lockup release for Contemporary Amperex Technology (CATL) (3750 HK), along with a number of other placements.


ECM Weekly (24 November 2025) - CATL, Hengrui, Hongqiao, WT Micro, SBI Shinsei, NS Group, Ultragreen

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Suzhou Ribo Life Science / Equity Capital Markets

<ul>
<li>The delivery system is a crucial element that drives the development/iteration of innovative oligonucleotide therapeutics. Ribo has mastered both GalNAc and LNP technologies, whose effectiveness/safety have been verified and recognized.</li>
<li>The valuation fluctuations not only reflect the market's prudence towards commercialization prospects of small nucleic acid drugs, but also highlight the balance problem between Ribo’s R&amp;D investment and profit model.</li>
<li>Since Sirnaomics’ delivery technologies have not been proven or validated scientifically, Ribo’s valuation should be higher than Sirnaomics.Valuation outlook is based on the druggability and commercialization performance of Ribo’s pipelines. </li>
</ul>


The delivery system is a crucial element that drives the development/iteration of innovative oligonucleotide therapeutics. Ribo has mastered both GalNAc and LNP technologies, whose effectiveness/safety have been verified and recognized.
The valuation fluctuations not only reflect the market's prudence towards commercialization prospects of small nucleic acid drugs, but also highlight the balance problem between Ribo’s R&amp;D investment and profit model.
Since Sirnaomics’ delivery technologies have not been proven or validated scientifically, Ribo’s valuation should be higher than Sirnaomics.Valuation outlook is based on the druggability and commercialization performance of Ribo’s pipelines. 


Pre-IPO Suzhou Ribo Life Science - The Strength, the Concerns and the Outlook for the SiRNA Unicorn

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

<ul>
<li>Suzhou Ribo Life is looking to raise at least US$100 million via a Hong Kong listing. CICC and Citi are the deal sponsors.</li>
<li>Ribo Life is a world leading company in the area of siRNA research.</li>
<li>The company's RBD4059 is potentially the first in class siRNA drug for thrombotic diseases.</li>
</ul>


Suzhou Ribo Life is looking to raise at least US$100 million via a Hong Kong listing. CICC and Citi are the deal sponsors.
Ribo Life is a world leading company in the area of siRNA research.
The company's RBD4059 is potentially the first in class siRNA drug for thrombotic diseases.


Suzhou Ribo Life Science (瑞博生物) Pre-IPO Quick View: Scarcity of SiRNA Player

China

Develops siRNA therapeutics for liver, cardiovascular, metabolic and renal diseases

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Suzhou Ribo Life Science (6938 HK)

ECM Weekly (24 November 2025) - CATL, Hengrui, Hongqiao, WT Micro, SBI Shinsei, NS Group, Ultragreen

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

Pre-IPO Suzhou Ribo Life Science - The Strength, the Concerns and the Outlook for the SiRNA Unicorn

Ribo's delivery technologies drives innovative therapeutics, but valuation fluctuations reflect market's caution on profit model. Future valuation...

Xinyao (Criss) Wang

Suzhou Ribo Life Science (瑞博生物) Pre-IPO Quick View: Scarcity of SiRNA Player

Suzhou Ribo Life plans to raise $100 million through a Hong Kong listing, with CICC and Citi as deal sponsors. They are a leading company in siRNA...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

ECM Weekly (24 November 2025) - CATL, Hengrui, Hongqiao, WT Micro, SBI Shinsei, NS Group, Ultragreen

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Sumeet Singh

Pre-IPO Suzhou Ribo Life Science - The Strength, the Concerns and the Outlook for the SiRNA Unicorn

​Ribo's delivery technologies drives innovative therapeutics, but valuation fluctuations reflect market's caution on profit model. Future valuation...

Xinyao (Criss) Wang

Suzhou Ribo Life Science (瑞博生物) Pre-IPO Quick View: Scarcity of SiRNA Player

​Suzhou Ribo Life plans to raise $100 million through a Hong Kong listing, with CICC and Citi as deal sponsors. They are a leading company in siRNA...

Ke Yan, CFA, FRM

Ribo's delivery technologies drives innovative therapeutics, but valuation fluctuations reflect market's caution on profit model. Future valuation...

Suzhou Ribo Life plans to raise $100 million through a Hong Kong listing, with CICC and Citi as deal sponsors. They are a leading company in siRNA...